Array Biopharma Inc. (ARRY) rated Mkt Outperform with price target $15 by Rodman & Renshaw
Rodman & Renshaw rated Mkt Outperform Array Biopharma Inc. (NASDAQ: ARRY) on 05/07/2008. Previously Rodman & Renshaw rated Buy Array Biopharma Inc. (NASDAQ:
ARRY) on 08/13/2007., when the stock price was $10.47. Since then, Array Biopharma Inc. has lost 62.66% as of 07/18/2014's recent price of $3.91. If you would have followed the previous Rodman & Renshaw's recommendation on ARRY, you would have lost 62.65% of your investment in 2531 days.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.
Rodman & Renshaw
is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.